Clinical Trials
31 trialsFRAmework-01
Eli Lilly and Company
DO-01
Daiichi Sankyo
MAESTRA 2
Incyte Corporation
TroFuse-021
Merck Sharp & Dohme LLC
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
ASPENOVA
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer
The First Hospital of Jilin University
TroFuse-022
Merck Sharp & Dohme LLC
RAINFOL-04
Genmab
OVATION-3
Imunon
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
HOTT
GOG Foundation
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
PHOCUS
Charles University, Czech Republic
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
FOCUS / KOV-04
National Cancer Center, Korea
SENTOV II
Instituto de Investigacion Sanitaria La Fe
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Hansoh BioMedical R&D Company
SALVOVAR
ARCAGY/ GINECO GROUP
ESTANVO
Centre Francois Baclesse
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
NX Development Corp
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
MOVES
Tampere University Hospital
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Tongji Hospital
CHIPRO
Chipscreen Biosciences, Ltd.
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
MOGCT-01
Shandong University
SCST-01
Shandong University
MITO 35B
National Cancer Institute, Naples
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Fudan University